We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

By LabMedica International staff writers
Posted on 24 Nov 2025

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. More...

Despite TB infecting 10 million people yearly, the immune mechanisms driving EPTB have remained unclear. A new study now maps the disease’s molecular activity in blood, identifying immune patterns that could lead to targeted therapies and non-invasive diagnostic tests.

In the collaborative study, researchers at the German Center for Infection Research (DZIF), Braunschweig, Germany) used blood samples from EPTB patients for applying multi-omics profiling, including single-cell RNA sequencing, to chart how immune cells communicate during infection.

The approach revealed complex signaling networks involving interferon and interleukin-1 pathways, as well as activation patterns of T cells and natural killer cells. Based on these molecular interactions, researchers identified three distinct “immunotypes,” each representing a unique disease course. The findings, published in Nature Communications, show that these immunotypes expose new biological mechanisms that shape how EPTB develops and progresses.

In addition to immune profiling, the team constructed gene expression–based biomarkers that accurately differentiated extrapulmonary from pulmonary TB. Current diagnosis of EPTB often requires invasive tissue biopsy; however, the newly identified blood signatures could serve as a future non-invasive diagnostic tool. These markers may help clinicians detect EPTB earlier, classify disease severity, and tailor treatments more precisely.

The investigators emphasize that integrating clinical data was essential to correctly interpret molecular findings and connect them to real patient outcomes. Their blood-based biomarker panel is now being validated in the larger mEX-TB clinical study, marking a step towards translation into clinical practice.

"These findings have the potential to substantially advance the diagnosis and treatment of tuberculosis and to facilitate the development of targeted, personalized therapies," said Dr. Thomas Ulas, a bioinformatician at the DZNE.

Related Links:
DZIF


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New research demonstrates that an electrical “fingerprint” on extracellular vesicles can be exploited to enrich cancer-associated signals (Image Credit: Shutterstock)

Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer

Pancreatic cancer is often diagnosed only after it has spread, contributing to a five-year survival rate of 13%. Standard blood-based analyses can struggle to distinguish tumor signals from the background... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.